B
Bionyra Pharma
Next-generation biologics for immune-mediated inflammatory diseases
About Bionyra Pharma
Bionyra Pharma is a Paris- and Boston-based clinical-stage biopharmaceutical company founded in 2025 with Sofinnova Partners and CEO Dr Frédéric Marrache, a former Sanofi global project head for immunology and inflammation. It develops next-generation mono and multispecific antibodies with half-life extension for immune-mediated inflammatory diseases, including BYN-002 (TL1A mAb, Phase 1 enrolled), BYN-003 (TL1A×IL-23p19 bispecific in Phase 1) and BYN-001 (IL-25 mAb, IND-stage for atopic dermatitis). Assets were in-licensed from partners including TrueLab Biopharmaceutical and NovaRock Biotherapeutics. In June 2026 Bionyra launched with an oversubscribed €143 million ($165 million) Series A co-led by Jeito Capital and Sofinnova Partners, with Arkin Bio, Sanofi Ventures, Sixty Degree Capital, Vives Partners and Apollo Health Ventures, to advance clinical programmes in IBD and dermatology. Sources: EU-Startups 22 Jun 2026.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2025
- Headquarters
- Paris, France
- Open positions
- None listed
- Dealroom signal
- 56.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Drug Development, Inflammatory Diseases, Immune System, DT and LS
- Business model
- Manufacturing
- Client focus
- B2B
Knowledge graph
News
More headlines
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Jun 2026 | $165M | $660M | Vives Partners · Apollo Health Ventures · Jeito Capital · Arkin Capital | ↗ |
Growth signals
Latest recorded traffic for Bionyra Pharma is 1.5K monthly website visits.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Bionyra Pharma in the Paris ecosystem
The Bionyra Pharma office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A7 investors entered at this stage
Jeito Capital
Sofinnova Partners
Vives Partners
Apollo Health Ventures
Arkin Capital
Sanofi Ventures
Sixty Degree Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Bionyra Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Bionyra Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.